The association between a carrier state of FMR1 premutation and numeric sex chromosome variations.


Journal

Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 21 09 2022
accepted: 13 01 2023
pmc-release: 01 03 2024
pubmed: 2 2 2023
medline: 25 3 2023
entrez: 1 2 2023
Statut: ppublish

Résumé

Women carriers of FMR1 premutation are at increased risk of early ovarian dysfunction and even premature ovarian insufficiency. The aim of this study was to examine a possible association between FMR1 permutation and numeric sex chromosome variations. A retrospective case-control study conducted in the reproductive center of a university-affiliated medical center. The primary outcome measure was the rate of sex chromosomal numerical aberrations, as demonstrated by haplotype analyses, in FMR1 premutation carriers compared to X-linked preimplantation genetic testing for monogenic/single gene defect (PGT-M) cycles for other indications that do not affect the ovarian follicles and oocytes. A total of 2790 embryos with a final genetic analysis from 577 IVF PGT-M cycles were included in the final analysis. Mean age was similar between the groups, however, FMR1 carriers required more gonadotropins, and more women were poor responders with three or less oocytes collected. The ratio of embryos carrying a numeric sex chromosome variation was similar: 8.3% (138/1668) of embryos in the FMR1 group compared to 7.1% (80/1122) in the controls. A subgroup analysis based on age and response to stimulation has not demonstrated a significant difference either. Although carriers of FMR1 premutation exhibit signs of reduced ovarian response, it does not seem to affect the rate of numeric sex chromosomal variation compared to women undergoing PGT-M for other indications. This suggests that the mechanism for chromosomal number aberrations in women at advanced maternal age are different to those FMR1 premutation carriers with poor ovarian reserve.

Identifiants

pubmed: 36723762
doi: 10.1007/s10815-023-02730-1
pii: 10.1007/s10815-023-02730-1
pmc: PMC10033765
doi:

Substances chimiques

Fragile X Mental Retardation Protein 139135-51-6
FMR1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

683-688

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Am J Med Genet. 2002 Jun 1;110(1):3-10
pubmed: 12116264
Hum Reprod. 2016 Jan;31(1):158-68
pubmed: 26537920
Fertil Steril. 2014 Mar;101(3):656-663.e1
pubmed: 24355045
Fertil Steril. 2007 Mar;87(3):456-65
pubmed: 17074338
Cell. 1991 Aug 23;66(4):817-22
pubmed: 1878973
Mol Cytogenet. 2021 May 10;14(1):25
pubmed: 33971935
Mutat Res Rev Mutat Res. 2020 Jul - Sep;785:108320
pubmed: 32800274
Front Cell Neurosci. 2017 May 05;11:128
pubmed: 28529475
Obstet Gynecol. 2017 Mar;129(3):e41-e55
pubmed: 28225426
Nat Rev Genet. 2001 Apr;2(4):280-91
pubmed: 11283700
Reprod Biomed Online. 2007 Apr;14(4):515-21
pubmed: 17425837
PLoS One. 2014 Aug 25;9(8):e105121
pubmed: 25153074
Hum Genet. 2013 Sep;132(9):1001-13
pubmed: 23620267
Am J Med Genet. 2000 Mar 13;91(2):144-52
pubmed: 10748416
Mol Cytogenet. 2022 Mar 21;15(1):11
pubmed: 35313946
Hum Reprod. 2018 Aug 1;33(8):1489-1498
pubmed: 30010882
Mol Hum Reprod. 2016 Jun;22(6):384-96
pubmed: 26965313
Hum Reprod. 2008 Nov;23(11):2596-608
pubmed: 18664475
Hum Reprod. 1993 Dec;8(12):2185-91
pubmed: 8150922
Genome Med. 2012 Dec 21;4(12):100
pubmed: 23259642
Obstet Gynecol. 2013 Jan;121(1):71-7
pubmed: 23262930
PLoS Genet. 2014 Apr 17;10(4):e1004294
pubmed: 24743386

Auteurs

Mira Malcov (M)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Ophir Blickstein (O)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Dana Brabbing-Goldstein (D)

Genetic Institute at Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Adi Reches (A)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Genetic Institute at Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yael Kalma (Y)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Yuval Fouks (Y)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Boston IVF-The Eugin Group, Waltham, MA, USA.

Foad Azem (F)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Yoni Cohen (Y)

IVF Unit, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. yonni.co@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH